Compositions and methods are described for the preparation and use of proliposomales and liposomal formulations of chemotherapeutic agents.Proliposomales and liposomal formulations of chemotherapeuticAs well as the Drugs and dosage forms that include these formulations can be used with Treatment regimens for Cancer and bladder urothelial cancer.Thus, the formulations and dosage forms are Medicines to treat cancers of the bladder by intravesical Administration and to treat urothelial cancers.The formulations according to the request include (a) a Taxane (e.g.Paclitaxel, docetaxel or Cisplatin), (b) a First phospholipid dimyristoyl - 1.2 - sn glycero Phosphocholine (DMPC) - 3 - (c) and a Second dimiristil phospholipid phosphatidyl glycerol, sodium (dmpg).Proliposomales liposome formulations are in contact with an aqueous vehicle.Claim 1: proliposomal dispersion Powder, which comprises (a) a Taxane or cisplatin, (b) 12 - dimyristoyl SN glycero Phosphocholine (DMPC) - 3 - (c) dimiristoil phosphatidyl glycerol and sodium (dmpg tokens), where relations are 1 a: B: C: (1.3 to 4.5): (0.4 - 2.5).Claim 2: proliposomal dispersion Powder according to claim 1, in which (a) is selected from the group consisting of a Taxane paclitaxel, docetaxel, cabazitaxel,Tesetaxel, DJ 927, TPI 287, larotaxel, ortataxel, DHA Paclitaxel and mixtures thereof.Claim: a 4 proliposomal dispersion Powder according to claim 1,In which (a) is cisplatin and dispersion also comprises (d) cholesterol and weight Relations of a: B: C: D is 1: (2.5 - 4.5): (1.0 - 2.5): (0.5 - 1).Claim 7: a Pharmaceutical composition comprising a dispersion proliposomal Powder according to any one of claims 1 - 6 and at least one component farmacéuticamentAnd acceptable.Se describen composiciones y métodos para la preparación y uso de formulaciones proliposomales y liposomales de agentes quimioterapéuticos. Las formulaciones proliposomales y liposomales de quimioterapéuticos, como así también los medicamentos y formas de dosif
